| 50 | 0 | 175 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨La蛋白抑制剂Comp 1120在增强卵巢癌细胞对卡铂的敏感性中的作用机制。方法 使用A2780卵巢癌细胞株评估Comp 1120与卡铂联合使用的效果，特别关注P53结合蛋白1(53BP1)在此过程中的作用。采用Western blot、TUNEL实验和流式细胞术评估细胞凋亡情况。结果 Western blot分析显示，在卡铂与Comp 1120联合处理下，A2780卵巢癌细胞中促凋亡蛋白Caspase-3和BAX的表达显著上调（P <0.01），而抗凋亡蛋白Bcl-2的表达下调（P <0.01）。TUNEL实验和流式细胞术进一步证实，卡铂与Comp 1120联合使用显著促进了细胞凋亡（P <0.01）。所有实验结果均显示，这种促凋亡效应依赖于53BP1的表达；在53BP1基因沉默的细胞中，联合处理的促凋亡效应显著减弱（P <0.01），提示Comp 1120增强卡铂敏感性通过53BP1调控实现。结论 La蛋白抑制剂Comp 1120能有效增强卵巢癌细胞对卡铂的敏感性，其作用机制可能涉及对53BP1途径的调节。
Abstract：AIM To explore the role of La protein inhibitor Comp 1120 in enhancing the sensitivity of ovarian cancer cells to carboplatin. METHODS The effect of the combined use of Comp 1120 and carboplatin was evaluated using the A2780 ovarian cancer cell line, with a particular focus on the role of 53BP1 in this process. Cell apoptosis was assessed using Western blot, TUNEL assays, and flow cytometry. RESULTS Western blot analysis showed that in A2780 ovarian cancer cells treated with the combination of carboplatin and Comp 1120, the expressions of pro-apoptotic proteins Caspase-3 and BAX were significantly upregulated(P < 0.01), while the expression of the anti-apoptotic protein Bcl-2 was downregulated(P < 0.01).TUNEL assay and flow cytometry further confirmed that the combination of carboplatin and Comp 1120 significantly promoted cell apoptosis(P < 0.01). All experimental results indicated that this pro-apoptotic effect depended on the expression of 53BP1. The pro-apoptotic effect of the combined treatment was significantly reduced in cells with 53BP1 gene silencing(P < 0.01), suggesting that Comp 1120 enhanced carboplatin sensitivity through 53BP1 regulation. CONCLUSION This study demonstrates that the La protein inhibitor Comp 1120 can effectively enhance the sensitivity of ovarian cancer cells to carboplatin, likely involving modulation of the 53BP1 pathway.
[1] GAONA-LUVIANO P, MEDINA-GAONA L A, MAGA?A-PéREZ K. Epidemiology of ovarian cancer[J]. Chin Clin Oncol, 2020,9(4):47.
[2] FUJIWARA K, MARKMAN M, MORGAN M, et al. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer[J].Gynecol Oncol, 2005, 97(1):10.
[3] LOKICH J, ANDERSON N. Carboplatin versus cisplatin in solid tumors:an analysis of the literature[J]. Ann Oncol, 1998, 9(1):13.
[4] ORTIZ M, WABEL E, MITCHELL K, et al. Mechanisms of chemotherapy resistance in ovarian cancer[J]. Cancer Drug Resist, 2022, 5(2):304.
[5] XIA X Y, LI Z K, LI Y J, et al. LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p/FOXP1 axis[J]. J Gynecol Oncol, 2022,33(6):e81.
[6] EMBABY A, KUTZERA J, GEENEN J J, et al. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53mutated ovarian cancer:a biomarker-enriched phase II study[J].Gynecol Oncol, 2023, 174:239.
[7] PIGNATA S, LORUSSO D, JOLY F, et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatinbased doublet alone in patients with platinum-sensitive ovarian cancer:a randomised, phase 3 trial[J]. Lancet Oncol, 2021,22(2):267.
[8] WETHINGTON S L, SHAH P D, MARTIN L, et al. Combination ATR(ceralasertib)and PARP(olaparib)inhibitor(CAPRI)trial in acquired PARP inhibitor-resistant homologous recombinationdeficient ovarian cancer[J]. Clin Cancer Res, 2023, 29(15):2800.
[9] SOMMER G, HEISE T. Role of the RNA-binding protein La in cancer pathobiology[J]. RNA Biol, 2021, 18(2):218.
[10] HOPKINS T G, MURA M, AL-ASHTAL H A, et al. The RNAbinding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer[J]. Nucleic Acids Res, 2016, 44(3):1227.
[11] HUANG X, ZHU J L, LI Y Y, et al. La protein regulates protein expression by binding with the mRNAs of target genes and participates the pathological process of ovarian cancer[J]. Front Oncol, 2022, 12:763480.
[12] LI Y Y, HUANG X, TANG J. Inhibiting the growth of ovarian cancer cells in vitro and in vivo by a small molecular inhibitor targeting La-RNA interactions[J]. Eur J Pharmacol, 2023, 940:175471.
[13] KABRANI E, SAHA T, DI VIRGILIO M. DNA repair and antibody diversification:the 53BP1 paradigm[J]. Trends Immunol, 2023,44(10):782.
[14] PANIER S, BOULTON S J. Double-strand break repair:53BP1comes into focus[J]. Nat Rev Mol Cell Biol, 2014, 15(1):7.
[15] BUNTING S F, CALLéN E, WONG N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks[J]. Cell, 2010, 141(2):243.
[16] SKULIMOWSKI M, BOURBONNAIS J, MALAQUIN N, et al.53BP1 mediates sensitivity to chemotherapy and is associated with poor clinical outcomes in high-grade serous ovarian cancer[J].bioRxiv, 2023:2023.09. 30.560286.
[17] ZHOU J B, KANG Y, CHEN L, et al. The drug-resistance mechanisms of five platinum-based antitumor agents[J]. Front Pharmacol, 2020, 11:343.
[18] MCMULLEN M, KARAKASIS K, MADARIAGA A, et al.Overcoming platinum and PARP-inhibitor resistance in ovarian cancer[J]. Cancers, 2020, 12(6):1607.
[19] ZHANG C Y, XU C, GAO X Y, et al. Platinum-based drugs for cancer therapy and anti-tumor strategies[J]. Theranostics, 2022,12(5):2115.
[20] LE SAUX O, RAY-COQUARD I, LABIDI-GALY S I. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer[J]. Semin Cancer Biol, 2021, 77:127.
[21] HUANG X, TANG J. Human La protein:an RNA-binding protein involved in ovarian cancer development and multidrug resistance[J]. Onco Targets Ther, 2020, 13:10721.
[22] FAN X T, ROSS D D, ARAKAWA H, et al. Impact of system L amino acid transporter 1(LAT1)on proliferation of human ovarian cancer cells:a possible target for combination therapy with antiproliferative aminopeptidase inhibitors[J]. Biochem Pharmacol,2010, 80(6):811.
[23] SOMMER G, ROSSA C, CHI A C, et al. Implication of RNAbinding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells[J]. PLoS One, 2011, 6(10):e25402.
基本信息:
DOI：10.19577/j.1007-4406.2025.02.001
中图分类号:R737.31
引用信息:
[1]李俊慜,朱佳蕾,汤静.La蛋白抑制剂Comp 1120通过53BP1途径增强卵巢癌细胞对卡铂的敏感性[J].中国临床药学杂志,2025,34(02):81-86.DOI:10.19577/j.1007-4406.2025.02.001.
基金信息:
中华医学会临床药学分会2023年度临床药学科研基金（编号Z-2021-46-2101-2023）; 上海市青浦区卫生健康系统第五轮学科带头人培养计划（编号XD2023-10）